Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVIDITY BIOSCIENCES, INC.

(RNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
21.63(c) 22.13(c) 22.1(c) 22.09(c) 21.52(c) Last
163 717 254 764 154 937 150 192 229 456 Volume
-5.67% +2.31% -0.14% -0.05% -2.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,56 M - -
Net income 2021 -113 M - -
Net cash position 2021 394 M - -
P/E ratio 2021 -7,83x
Yield 2021 -
Sales 2022 6,58 M - -
Net income 2022 -154 M - -
Net cash position 2022 313 M - -
P/E ratio 2022 -6,38x
Yield 2022 -
Capitalization 983 M 983 M -
EV / Sales 2021 77,9x
EV / Sales 2022 102x
Nbr of Employees 71
Free-Float 90,9%
More Financials
Company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company focuses on oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC), designed to overcome the limitations of oligonucleotide-based therapies to treat a range of serious diseases. It utilizes its AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and... 
Sector
Pharmaceuticals
Calendar
11/16Earnings Release
More about the company
Ratings of Avidity Biosciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about AVIDITY BIOSCIENCES, INC.
09/07AVIDITY BIOSCIENCES : Evercore ISI Starts Avidity Biosciences at Outperform with $50 Price..
MT
09/01Health Care Stocks Reverse Losses as Biotechs Rise
MT
09/01Top Midday Decliners
MT
09/01Health Care Stocks Edging Lower, Biotechs Working to Limit Declines
MT
09/01AVIDITY BIOSCIENCES : Shares Slide After Chief Medical Officer Steps Down
MT
09/01AVIDITY BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/01Avidity Biosciences, Inc. Announces Executive Changes
CI
08/31AVIDITY BIOSCIENCES : to Participate in Upcoming Investor Conferences
PR
08/25AVIDITY BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/25AVIDITY BIOSCIENCES : Announces Changes to its Board of Directors
PR
08/25Avidity Biosciences, Inc. Announces Board Changes
CI
08/24AVIDITY BIOSCIENCES' : Myotonic Dystrophy Treatment Candidate Gets Orphan Designation in E..
MT
08/24AVIDITY BIOSCIENCES : European Medicines Agency (EMA) Grants Orphan Designation for AOC 10..
PR
08/16AVIDITY BIOSCIENCES : Enters Into Collaboration with FSHD Clinical Trial Network to Suppor..
PR
08/16Avidity Biosciences, Inc. Enters into Collaboration with FSHD Clinical Trial Network to..
CI
More news
News in other languages on AVIDITY BIOSCIENCES, INC.
09/01Les actions du secteur de la santé inversent leurs pertes alors que les biotechnologies..
09/01Les actions du secteur de la santé en baisse, les biotechs s'efforcent de limiter les b..
09/01Les actions d'Avidity Biosciences chutent après le départ du médecin-chef
More news
Analyst Recommendations on AVIDITY BIOSCIENCES, INC.
More recommendations
Chart AVIDITY BIOSCIENCES, INC.
Duration : Period :
Avidity Biosciences, Inc. Technical Analysis Chart | RNA | US05370A1088 | MarketScreener
Technical analysis trends AVIDITY BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 21,52 $
Average target price 46,40 $
Spread / Average Target 116%
EPS Revisions
Managers and Directors
Sarah Boyce President, Chief Executive Officer & Director
Michael F. MacLean Chief Financial & Accounting Officer
Troy E. Wilson Non-Executive Chairman
Arthur A. Levin Chief Scientific Officer
W. Michael Flanagan Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
AVIDITY BIOSCIENCES, INC.-15.67%983
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.16.50%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336